VISTA also predicts the poor prognosis of glioma patients (P = 0.0085); VISTA may co-express with PD1, and high expression of both the immune checkpoints indicate worse survival (P < 0.0001), which is associated with the negative regulation of VISTA in the glioma microenvironment [72]. This evidence concerns the gene PDCD1 and central nervous system cancer.